10 July,2021 05:20 PM IST | | IANS
This file handout picture provided by the Russian Direct Investment Fund shows the vaccine against the COVID-19 coronavirus disease, developed by the Gamaleya Research Institute of Epidemiology and Microbiology. Picture/ Russian Direct Investment Fund / A
Russia-s Sputnik V vaccine has been found to be more than 95 per cent effective against Covid-19 in the second interim analysis of Phase 3 clinical trial data, its developers said on Tuesday.
The analysis was based on data from volunteers obtained 42 days after the first dose -- which corresponds with 21 days after the second dose, Gamaleya National Research Centre for Epidemiology and Microbiology of the Russian Health Ministry and Russian Direct Investment Fund RDIF, said.
And based on data obtained 28 days after administering the first dose - seven days after the second dose, the efficacy of the Sputnik V vaccine was found to be 91.4 per cent.
"The data demonstrating high efficacy of the Sputnik V vaccine gives us hope that we will soon obtain the most important tool in the fight against the pandemic of the novel coronavirus infection," Russian Health Minister Mikhail Murashko said in a statement.
ALSO READ
Moscow offers debt forgiveness to new recruits, AP sees wreckage of new Russian missile
Moscow bans adoption of Russian children to countries that allow gender transition
Russia launches intercontinental missile in attack for first time in Ukraine war
Ukraine fires into Russia for first time using missiles provided by the West
Moscow says Ukraine fired 6 US-made longer-range missiles into Russia
According to the protocol of Phase III clinical trials of the Sputnik V vaccine, its interim efficacy is calculated at three statistically significant representative control points -- upon reaching 20, 39 and 78 cases of novel coronavirus infection among volunteers both in the placebo group and in the group that received the vaccine.
The second interim analysis of the Sputnik V vaccine efficacy was carried out on the basis of 39 confirmed cases identified in the placebo group 31 cases and in the vaccine group 8 cases.
The Russian vaccine uses two different vectors based on the human adenovirus, rather than using one and the same vector for two doses.
The next interim data analysis will be conducted upon reaching the third control point of 78 confirmed coronavirus cases among the study participants. Final data analysis will be available by the end of Phase 3 clinical trials involving 40,000 volunteers.
Drug maker AstraZeneca on Monday said that its Covid-19 vaccine, developed with Oxford University, was up to 90 percent effective, making it one of the major drug companies after Pfizer and Moderna to have reported late-stage data for a potential Covid-19 vaccine.
Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.
Mid-Day is now on Telegram. Click here to join our channel @middayinfomedialtd and stay updated with the latest news
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove without notice the content in its absolute discretion for any reason whatsoever
